Tin tức & Cập nhật
Xem bài viết Ung thư
Xem
Chỉ hiển thị Multimedia

Atezolizumab-bevacizumab combo trumps sorafenib for advanced HCC
27 Mar 2022
The combination of atezolizumab and bevacizumab is better than sorafenib at maintaining clinically meaningful survival benefits over the long term in patients with unresectable hepatocellular carcinoma (HCC), reports a recent update to the IMbrave150 study.
27 Mar 2022

Polymeric immunoglobulin receptor boosts cancer stemness, tumorigenesis in HCC patients
26 Mar 2022
Extracellular vesicles enriched with the polymeric immunoglobulin receptor molecule contributes to tumorigenesis and cancer stemness in patients with hepatocellular carcinoma (HCC), reports a recent study.
26 Mar 2022

Apalutamide for castration-resistant prostate cancer yields real-world results
25 Mar 2022
Patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) who have been initiated on apalutamide in a real-world setting appear to show prostate-specific antigen (PSA) response that is strong and consistent with that reported in clinical trials, as reported in a study.
25 Mar 2022





